SKYSONA has become the first FDA approved therapy to slow the progression of neurologic dysfunction in boys with cerebral adrenoleukodystrophy (CALD). The US Food and Drug Administration (FDA) has granted Accelerated Approval to bluebird bio’s SKYSONA (elivaldogene autotemcel), also known as eli-cel, in boys four to 17 years of age with early, active CALD. CALD […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!